Monoclonal antibodies (mAbs) have revolutionized targeted therapy, particularly in the fields of oncology, immunology, and infectious diseases. However, discovering a high-affinity variable region that binds precisely to a disease target is only the first half of the battle. Once an antibody binds to its antigen, its ability to recruit the body's immune system relies entirely on its Fc...